Australia Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
10.52-0.06 (-0.57%)
At close: 4:00PM EST

10.54 +0.02 (0.19%)
After hours: 6:30PM EST

Currency in USD

Valuation measures

Market cap (intra-day) 511.49B
Enterprise value 336.99B
Trailing P/E N/A
Forward P/E 13.84
PEG ratio (5-yr expected) 10.84
Price/sales (ttm)0.69
Price/book (mrq)1.15
Enterprise value/revenue 32.22
Enterprise value/EBITDA 68.02

Trading information

Stock price history

Beta (5Y monthly) 1.45
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 313.30
52-week low 36.25
50-day moving average 311.68
200-day moving average 310.13

Share statistics

Avg vol (3-month) 39.77M
Avg vol (10-day) 310.07M
Shares outstanding 51.1B
Float 1.09B
% held by insiders 11.02%
% held by institutions 151.78%
Shares short (11 Feb 2021) 434.47M
Short ratio (11 Feb 2021) 43.26
Short % of float (11 Feb 2021) 4N/A
Short % of shares outstanding (11 Feb 2021) 43.14%
Shares short (prior month 14 Jan 2021) 429.75M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Dec 2017
Ex-dividend date 426 Nov 2017
Last split factor 22:1
Last split date 330 Jun 2004

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020

Profitability

Profit margin -23.95%
Operating margin (ttm)18.34%

Management effectiveness

Return on assets (ttm)3.53%
Return on equity (ttm)-31.38%

Income statement

Revenue (ttm)16.66B
Revenue per share (ttm)15.21
Quarterly revenue growth (yoy)-0.30%
Gross profit (ttm)7.73B
EBITDA 4.61B
Net income avi to common (ttm)-3.99B
Diluted EPS (ttm)-3.64
Quarterly earnings growth (yoy)37.60%

Balance sheet

Total cash (mrq)2.18B
Total cash per share (mrq)1.99
Total debt (mrq)26.54B
Total debt/equity (mrq)239.90
Current ratio (mrq)0.99
Book value per share (mrq)9.14

Cash flow statement

Operating cash flow (ttm)1.22B
Levered free cash flow (ttm)1.73B